Industry Spotlight  |
Vaccines

Discussion Group Announcement

Edited by Tia Byer |
27 July 2022
Oxford Global’s next round of Biologics Discussion Groups announced.

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing biologics research and development today. The interactive sessions provide a focused networking opportunity for a handful of like-minded experts in an online format.

Bringing together an exclusive panel of key opinion leaders for an hour of specialist discussion, each session addresses the critical growth factors, challenges, and future opportunities for the expansive biologics field and market.

For the next round of Discussion Groups, we will be exploring cutting-edge vaccine technologies and applications, as well as developing the next generation of biotherapeutics. With an array of hand-picked panel experts lined-up to lead stimulating and thought-provoking debates, these exclusive sessions are not-to-be-missed!

1.) Advanced Vaccine Platforms & Technologies

Taking place Friday 9th September 2022 | 15:00 BST (09:00 EST)

Discussion Topics:

  • Vaccine platform technologies
  • Development of modern vaccine technologies (mRNA, viral vectors, DNA and rapid response platforms)
  • Industry opportunities and challenges

Discussion Leaders:

  • Wieslaw Swietnicki, Head Of Research And Development at Łukasiewicz Research Network – Institute of Industrial Organic Chemistry
  • Slobodanka Dina Manceva, Senior Scientist at Teva Pharma

Oxford Global’s Discussion Groups

2.) Exploring & Developing Various Biotherapeutics Modalities

Taking place Tuesday 18 October 2022 | 15:00 BST (09:00 EST)

Discussion Topics:

  • Accelerating the development of next-generation therapeutics
  • Overcoming challenges in analytical method development

Discussion Leaders:

  • Peter D. Westenskow, Senior Principal Scientist and Section Head at Roche Pharma Research & Early Development
  • Slobodanka Dina Manceva, Associate Director at Teva Pharma
  • Smita Raghava, Associate Principal Scientist at Merck
  • Jonathan Davis, Vice President of Innovation and Strategy at Invenra

ion Groups

3.) Universal Vaccines & Vaccine Therapeutics

Taking place Thursday 3 November 2022 | 15:00 GMT (11:00 EDT)

Discussion Topics:

  • Existing and Approved Immunotherapies
  • Broadening the Horizons for Immunotherapy
  • Understanding Mechanisms of Action

Discussion Leaders:

  • Mark Doherty, Senior Medical Manager at GSK
  • Slobodanka Dina Manceva, Senior Scientist at Teva Pharma

Attendance to our Discussion Groups is available to members of our Biologics Member Community. For more information about Membership, please click here.

Join Oxford Global‘s 2023 Biologics UK: In-Person event today. Happening in March, this 3-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.

Get your bi-weekly dose of industry news here and keep up to date with the latest ‘Industry Spotlight’ posts. For other Biologics content, please visit the Biologics Content Portal.

Share this article

Share on facebook
Share on twitter
Share on linkedin

Sign up for our monthly Biologics Newsletter

You may also be interested in...

Industry Spotlight
Children between one and nine years old to be given polio jab to curb the spread of the virus throughout the city.
17 August 2022
Industry Spotlight
How worrying is the new ‘Langya’ virus spreading in China?
12 August 2022

Continue browsing

Share this article

Share on facebook
Share on twitter
Share on linkedin

Join our Biologics mailing list

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biologics